Home›Stock Screener›Rossari Biotech›Intrinsic Value

Rossari Biotech Intrinsic Value

Rossari Biotech intrinsic value. Rossari Biotech (ROSSARI) median intrinsic value is ₹856.00 from 10 valuation models (range ₹128–₹1070), vs current price ₹428.00 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Browse Rossari Biotech annual reports for revenue, profit, balance sheet and cash flow data.

Market Price (CMP)
₹428.00
Primary Intrinsic Value
₹336.96
Market Cap
₹470.8 Cr
+100.0% Upside
Median Value
₹856.00
Value Range
₹128 - ₹1070
Assessment
Trading Below Calculated Value
Safety Margin
50.0%

ROSSARI Valuation Methods Summary — DCF, Graham Number & P/E

Rossari Biotech intrinsic value across 10 models vs current price ₹428.00 — upside/downside and value range per method. Analyse Rossari Biotech ownership pattern to track promoter, FII and institutional holdings.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹336.96 ₹269.57 - ₹404.35 -21.3% EPS: ₹28.08, Sector P/E: 12x
Book Value Method asset ₹1070.00 ₹963.00 - ₹1177.00 +150.0% Book Value/Share: ₹1211.82, P/B: 1.0x
Revenue Multiple Method revenue ₹856.00 ₹770.40 - ₹941.60 +100.0% Revenue/Share: ₹2541.82, P/S: 0.8x
EBITDA Multiple Method earnings ₹856.00 ₹770.40 - ₹941.60 +100.0% EBITDA: ₹352.00Cr, EV/EBITDA: 6x
Simple DCF (5Y) dcf ₹802.65 ₹642.12 - ₹963.18 +87.5% CF Growth: 15.0%, Discount: 15%
PEG Ratio Method growth ₹179.71 ₹161.74 - ₹197.68 -58.0% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹231.38 ₹208.24 - ₹254.52 -45.9% Revenue Growth: 6.0%, Adj P/E: 8.2x
ROE Based Valuation profitability ₹856.00 ₹770.40 - ₹941.60 +100.0% ROE: 11.7%, P/E Multiple: 12x
Graham Defensive Method conservative ₹875.00 ₹787.50 - ₹962.50 +104.4% EPS: ₹28.08, BVPS: ₹1211.82
Dividend Yield Method dividend ₹128.40 ₹115.56 - ₹141.24 -70.0% DPS: ₹0.50, Target Yield: 3.5%
Method Types: Earnings Asset DCF Growth Dividend Conservative

ROSSARI Intrinsic Value vs Market Price — All Valuation Models

Rossari Biotech fair value range ₹128–₹1070 vs current market price ₹428.00 across 10 valuation models. For current market price and key ratios, visit Rossari Biotech stock price NSE.

ROSSARI Intrinsic Value Analysis — Undervalued or Overvalued?

Rossari Biotech median intrinsic value ₹856.00, current price ₹428.00 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.

What is the intrinsic value of ROSSARI?

Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Rossari Biotech (ROSSARI) is ₹856.00 (median value). With the current market price of ₹428.00, this represents a +100.0% variance from our estimated fair value.

The valuation range spans from ₹128.40 to ₹1070.00, indicating ₹128.40 - ₹1070.00.

Is ROSSARI undervalued or overvalued?

Based on our multi-method analysis, Rossari Biotech (ROSSARI) appears to be trading below calculated value by approximately 100.0%.

ROSSARI Financial Health — Key Ratios vs Industry Benchmarks

Rossari Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 11.7% Industry Standard: 15%+ Above 10% Measures shareholder return efficiency
Operating Margin 12.0% Industry Standard: 20%+ Above 10% Indicates operational efficiency level
Asset Turnover Ratio 1.22x Industry Standard: 1.0x+ Above 1.0x Measures asset utilization efficiency

ROSSARI Cash Flow Quality — Operating & Free Cash Flow

Rossari Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹65 Cr ₹-45 Cr Positive Operating Cash Flow 6/10
March 2025 ₹137 Cr ₹46 Cr Positive Free Cash Flow 7/10
March 2024 ₹43 Cr ₹-9 Cr Positive Operating Cash Flow 6/10
March 2023 ₹152 Cr ₹62 Cr Positive Free Cash Flow 7/10
March 2022 ₹29 Cr ₹-121 Cr Positive Operating Cash Flow 6/10